Clinical Trial Update: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cetuximab plus docetaxel with low-dose fractionated radiation for head and neck squamous cell carcinoma was terminated; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Taxotere (docetaxel)

Snippet

Sponsor: University of Miami | Conditions: Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-05-11